Status:
Ready to upload
Record number:
1562
Adverse Occurrence type:
MPHO Type:
Estimated frequency:
N/A: Article proposes framework for risk assessment of donor tumor transmission for various tumor types
Time to detection:
N/A
Alerting signals, symptoms, evidence of occurrence:
N/A
Demonstration of imputability or root cause:
N/A
Groups audience:
Keywords:
Suggest new keywords:
Malignancy
Review
squamous cell carcinoma
carcinoma in situ (CIS) (new)
Bladder
Urothelial carcinoma (new)
thyroid carcinoma (new)
RCC (renal cell carcinoma)
Primary central nervous system tumor
CNS teratoma (new)
Breast cancer
Colon adenocarcinoma (new)
Melanoma
Choriocarcinoma
Leukemia
Lymphoma
Small cell neuroendocrine carcinoma
Metastatic disease
Sarcoma
Lung cancer
Paraganglioma (new)
Angiomyolipoma (new)
Pleomorphic adenoma (new)
Atrial myxoma (new)
Mesothelioma (new)
Renal oncocytoma
Pheochromocytoma (new)
Adrenal gland
Subject review
Reference attachment:
Suggest references:
Nalesnik, M.A.; Woodle, E.S.; DiMaio, J.M.; Vasudev, B.; Teperman, L.W.; Covington, S.; Taranto, S.; Gockerman, J.P.; Shapiro, R.; Sharma, V.; Swinnen, L.J.; Yoshida, A.; Ison, M.G. Donor-Transmitted Malignancies in Organ Transplantation: Assessment of Clinical Risk American journal of transplantation 2011; 11 (6) :1140 - 1147
Note:
Not sure how to classify this by malignancy category, I have "malignancy, other" which will make it difficult to find. It would be good to have it listed under each malignancy type. Is there any way to do this without duplicating the record multiple times? (MN)
-------------------------------------------------------------------------------------------------------------------------------------------
There are two alternatives in order to avoid the duplication of the record: to list the different malignancy types as key words or mention them as free text in the present record; to link the reference with existing records of the specific malignancy types and delete the present record - PLEASE INDICATE HOW TO PROCEED (EP)
______________________
I can't link to original reports because there are no original reports in this case. There will be many keywords, but that is probably the best approach.
I added the tumors that are discussed in this paper MN
Expert comments for publication:
DTAC (Disease Transmission Advisory Committee of UNOS) guidance article for assessing risk categories for specific tumor types with recommended clinical use. Benign tumors with certain risks (e.g. chance of malignant transformation) also included. Categories, estimated risk frequencies, and recommended clinical uses include: 1. No significant risk (0%); standard; 2. Minimal risk (0.1% or less but >0%); clinical judgment, informed consent; 3. Low risk (0.1-1%) use in recipients at significant risk without transplant, informed consent; 4. Intermediate risk (1-10%): generally not recommended for transplant except when expected survival without transplant is very short, informed consent; 5. High risk (>10%), transplant discouraged except in rare and extreme circumstances, informed consent; 6. Unknown risk (evaluation for risk factors incomplete or no relevant literature to assess risk), use based on clinical judgment and informed consent.